Saturday 17 October 2026
Export SNTI’s income statement to Excel — free account
Senti Biosciences, Inc.
SNTI Healthcare Biotechnology
Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023. In the quarter to June 2026, revenue fell 98.7%, EPS grew 26.8% and free cash flow fell 7.48%, each against the same quarter a year earlier.
0.22
0.04
−15.38%
Follow SNTI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (466.46%) | (255.03%) | (393.35%) | (394.62%) |
+8 more TTM periods Free account |
|
| (97.52%) | (85.19%) | (82.43%) | (86.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(571.34%) | (408.39%) | (276.92%) | (191.69%) | |
Average Days of Receivables |
1,376.28 | 108.35 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.22) | (1.19) | (1.94) | (1.91) | |
Free Cash Flow |
(37.94) | (36.94) | (43.64) | (50.21) | |
Capital Expenditures |
0.11 | (0.07) | (0.19) | (0.13) | |
| Other line items | |||||
Cash ROIC |
(1,238.96%) | (321.26%) | (198.28%) | (246.55%) | |
Accounts Receivable Turnover |
0.30 | 1.73 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,394.80% | 1,303.30% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,930.43% | 980.99% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
408.18% | 225.73% | 0.00% | 0.00% | |
Operating CF/Net income |
0.77 | 0.72 | 0.71 | 1.05 | |
Depreciation/Fixed assets |
0.28 | 0.28 | 0.28 | 0.20 | |
Capex/Depreciation |
0.04 | (0.02) | (0.05) | (0.04) | |
Revenue per Share |
0.04 | 0.08 | 0.00 | 0.00 | |
Operating CF per Share |
(1.22) | (1.19) | (1.93) | (1.91) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
(0.09) | 0.03 | 0.00 | 0.00 |
Columns are period end dates